Literature DB >> 24273036

Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis.

Amy E Armstrong1, Jamie Dargart, Jennifer Reichek, David O Walterhouse, Debora Matossian, Richard A Cohn, Yasmin Gosiengfiao.   

Abstract

Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6-year-old child with high-risk neuroblastoma who developed renal failure requiring long-term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20 mg/m(2)/day and oral temozolomide 100 mg/m(2)/day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemotherapy; hemodialysis; irinotecan; neuroblastoma; renal failure; temozolomide

Mesh:

Substances:

Year:  2013        PMID: 24273036     DOI: 10.1002/pbc.24869

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Pretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cells.

Authors:  Sebastian Braun; Inge Bauer; Benedikt Pannen; Robert Werdehausen
Journal:  BMC Anesthesiol       Date:  2015-10-17       Impact factor: 2.217

2.  Individualized treatment of breast cancer with chronic renal failure: A case report and review of literature.

Authors:  Jie-Hui Cai; Jie-Hua Zheng; Xiao-Qi Lin; Wei-Xun Lin; Juan Zou; Yao-Kun Chen; Zhi-Yang Li; Ye-Xi Chen
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

3.  Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report.

Authors:  Liu Yang; Xiao-chen Zhang; Su-feng Yu; Hua-Qing Zhu; Ai-ping Hu; Jian Chen; Peng Shen
Journal:  BMC Cancer       Date:  2015-11-18       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.